Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The childhood obesity prevalence has increased dramatically in the last decades, affecting more than 340 million children worldwide. This condition is the major risk factor for a set of metabolic abnormalities, also known as metabolic syndrome, a condition that reduce life expectancy by 5-20 years. Changes in the global food system, and the increased consumption of ultra-processed foods (UPFs), may have contributed to the increase in the prevalence of childhood obesity and related morbidities. The mechanisms by which UPFs might promote obesity and metabolic syndrome could be multiple and not completely identified.
The Ultra-processed Food in Obesity (UFO) Project has been designed to investigate the potential associations between UPFs intake and MetS in pediatric subjects
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 | Pediatric patients with obesity | ||
| Group 2 | Pediatric patients with obesity complicated by Metabolic Syndrome | ||
| Group 3 | Age- and sex-matched healthy controls |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Dietary UPF intake | The assessment of dietary UPF intake will be carried out through a 7-day food diary. | At enrollment |
| Measure | Description | Time Frame |
|---|---|---|
| Daily intake of energy and nutrients | The daily intake of energy (kcal) and nutrients will be carried out through a 7-day food diary. | At enrollment |
| Daily dietary intake of AGEs | The intake of Advanced Glycation Endproducts (mostly present in UPFs). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Pediatric subjects of caucasian ethnicity, of both sexes, aged ≥6 and ≤18 years, with a sure diagnosis of obesity (Group 1), of obesity complicated by Metabolic Syndrome (Group 2), and age- and sex-matched healthy controls (Group 3).
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Traslational Medical Science - University of Naples Federico II | Recruiting | Naples | 80131 | Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009767 | Obesity, Morbid |
| D024821 | Metabolic Syndrome |
| ID | Term |
|---|---|
| D009765 | Obesity |
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
| At enrollment |
| Skin AGEs levels | The skin accumulation of AGEs in the subcutaneous. | At enrollment |
| RAGE expression in peripheral blood mononuclear cells | The expressione of the AGEs receptor in peripheral blood mononuclear cells. | At enrollment |
| Soluble form of RAGE expression | The expressione of the AGEs receptor in the serum. | At enrollment |
| Mitochondrial metabolism | The mitochondrial metabolism through the Seahorse XFp analyzer. | At enrollment |
| Oxidative stress | Oxidative stress biomarkers. | At enrollment |
| Interleukin-6 | Serum levels of Interleukin-6. | At enrollment |
| MicroRNA-221 expression | MicroRNA-221 expression in peripheral blood mononuclear cells. | At enrollment |
| Leptin | Serum levels of leptin. | At enrollment |
| Ghrelin | Serum levels of ghrelin. | At enrollment |
| D009750 |
| Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D007333 | Insulin Resistance |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |